These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18703133)

  • 21. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
    Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
    AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection.
    Zangerle R; Widner B; Quirchmair G; Neurauter G; Sarcletti M; Fuchs D
    Clin Immunol; 2002 Sep; 104(3):242-7. PubMed ID: 12217334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection.
    Jenabian MA; El-Far M; Vyboh K; Kema I; Costiniuk CT; Thomas R; Baril JG; LeBlanc R; Kanagaratham C; Radzioch D; Allam O; Ahmad A; Lebouché B; Tremblay C; Ancuta P; Routy JP;
    J Infect Dis; 2015 Aug; 212(3):355-66. PubMed ID: 25616404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection.
    Neurauter G; Zangerle R; Widner B; Quirchmair G; Sarcletti M; Fuchs D
    Adv Exp Med Biol; 2003; 527():317-23. PubMed ID: 15206745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
    Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
    PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.
    Kumarasamy N; Poongulali S; Beulah FE; Akite EJ; Ayuk LN; Bollaerts A; Demoitié MA; Jongert E; Ofori-Anyinam O; Van Der Meeren O
    Medicine (Baltimore); 2018 Nov; 97(45):e13120. PubMed ID: 30407329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.
    Lee J; Lee JY; Meade CS; Cohn M; Chahine A; Dilworth SE; Magidson JF; Gouse H; Fuchs D; Carrico AW
    J Neurovirol; 2020 Oct; 26(5):779-784. PubMed ID: 32728896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy.
    Premeaux TA; Javandel S; Hosaka KRJ; Greene M; Therrien N; Allen IE; Corley MJ; Valcour VG; Ndhlovu LC
    Front Immunol; 2020; 11():1321. PubMed ID: 32695109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulant use, HIV, and immune dysregulation among sexual minority men.
    Cherenack EM; Chavez JV; Martinez C; Hirshfield S; Balise R; Horvath KJ; Viamonte M; Jimenez DE; Paul R; Dilworth SE; DeVries B; Pallikkuth S; Stevenson M; Alvarado TC; Pahwa S; Carrico AW
    Drug Alcohol Depend; 2023 Oct; 251():110942. PubMed ID: 37651812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zero CD4 count: a case of discordant CD4 response in a patient with well suppressed viral load.
    Raja K; Chandrasekar C; Krishnarajasekhar OR; Manoharan G
    Indian J Med Microbiol; 2013; 31(3):298-302. PubMed ID: 23883722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
    Hurwitz BE; Klaus JR; Llabre MM; Gonzalez A; Lawrence PJ; Maher KJ; Greeson JM; Baum MK; Shor-Posner G; Skyler JS; Schneiderman N
    Arch Intern Med; 2007 Jan; 167(2):148-54. PubMed ID: 17242315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study.
    Shoptaw S; Stall R; Bordon J; Kao U; Cox C; Li X; Ostrow DG; Plankey MW
    Int J STD AIDS; 2012 Aug; 23(8):576-80. PubMed ID: 22930295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of gender and serum total cholesterol with CD4+ T cell count and HIV RNA load in antiretroviral-naïve individuals in Addis Ababa.
    Adal M; Howe R; Kassa D; Aseffa A; Petros B
    BMC Public Health; 2018 Jul; 18(1):943. PubMed ID: 30064395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.
    Gandhi RT; McMahon DK; Bosch RJ; Lalama CM; Cyktor JC; Macatangay BJ; Rinaldo CR; Riddler SA; Hogg E; Godfrey C; Collier AC; Eron JJ; Mellors JW;
    PLoS Pathog; 2017 Apr; 13(4):e1006285. PubMed ID: 28426825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.